Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
57.26 USD | +2.54% |
|
+7.35% | +108.22% |
Jul. 08 | Merus Begins Phase 2 Trial of Colorectal Cancer Drug Candidate | MT |
Jul. 08 | Merus Initiates Mid-stage Study of Colorectal Cancer Combination Therapy | MT |
Evolution of the average Target Price on Merus N.V.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
![Consensus](/images/consensus_flch.gif)
Consensus detail
Consensus revision (last 18 months)
Analysts covering Merus N.V.
Stifel Nicolaus | |
Canaccord Genuity | |
BMO Capital | |
Truist Securities | |
BofA Securities | |
HC Wainwright | |
Guggenheim | |
Needham & Co. | |
TD Cowen | |
Citigroup | |
SVB Securities LLC | |
EF Hutton | |
RBC Capital Markets | |
SVB Leerink | |
Roth Capital Partners | |
William Blair & Co. |
EPS Revisions
- Stock Market
- Equities
- MRUS Stock
- Consensus Merus N.V.